The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA.

A new study has found small amounts of liquid ketamine administered in a clinical setting can significantly reduce symptoms ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

A new study finds that oral ketamine significantly reduces PTSD symptoms, with 73% of participants seeing a 50% reduction in ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

Presenting House Bill 37 to an Idaho House committee, bill sponsor Rep. Bruce Skaug, R-Nampa called the firing squad “more ...

Letby lost two attempts in 2024 to challenge her convictions at the Court of Appeal. The Crown Prosecution Service previously ...